Clinical Trials Logo

Clinical Trial Summary

The health crisis linked to the coronavirus has had a significant impact on the mental health. The question of the repercussion of this crisis on the consumption of psychotropic drugs is crucial. It is all the more true in France, which was already among the countries with the highest consumption of psychotropic drugs before the crisis. Indeed, an increase in the number of reimbursements for anxiolytic, hypnotic and antidepressant drugs has been highlighted in the context of the health crisis, using data from the health insurance database. To enhance the understanding about the impacts of the health crisis on the use of psychotropic drugs, it is essential to characterize the evolution of the use at the individual level. The main objective is to assess the impact of the coronavirus-related health crisis on the consumption of psychotropic drugs by studying the trajectories of reimbursements. The secondary objective of the project is to evaluate the evolution of problematic consumption of psychotropic drugs in the context of the health crisis.


Clinical Trial Description

The project will allow studying the evolution of the use of psychotropics since the coronavirus-related health crisis according to the temporality of consumption (succession and/or concomitance of consumption) or their persistence over time. This project has two major aims: - Pharmacosurveillance: evaluation of the impact of psychotropic drug consumption in the context of the health crisis related to the coronavirus. The consumption of psychotropic drugs is a public health issue in France and concerns the entire general population. Even before the crisis, France was one of the countries in the world where the consumption of psychotropic drugs was the highest. - Scientific: use of an innovative methodology for assessing the impact of pharmaco-epidemiology (trajectories based on reimbursement data). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05395897
Study type Observational
Source Nantes University Hospital
Contact
Status Active, not recruiting
Phase
Start date January 1, 2023
Completion date December 13, 2024

See also
  Status Clinical Trial Phase
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Recruiting NCT01246765 - National Pregnancy Registry for Psychiatric Medications
Completed NCT01988311 - Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators Phase 1
Recruiting NCT06211517 - Drugs Experience for Adolescents With Anorexia
Not yet recruiting NCT05406102 - Remimazolam Improves the Safety in Elderly Patients Undergoing Gastrointestinal Endoscopy Phase 4
Completed NCT04922593 - Relative Bioavailability of LY03010 Compared to Listed Drug Phase 1
Completed NCT03114098 - Pharmacogenetics Anomaly Research in Children and Adolescents With Pharmacological Resistance to Psychotropic Drugs N/A
Completed NCT00294008 - A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR) Phase 4
Not yet recruiting NCT05897398 - SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY®